Intermediates useful for preparation of LpxC analogs and methods for their preparation
Patent Information
- Application Number
- CN202380031833.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-30
- Filing Date
- 2023-03-29
- Publication Date
- 2024-11-26
AI Technical Summary
然而,所描述的方法不可扩展,因为其仅提供产率为约13%的关键对映异构体纯的中间体(R)-4-(4-氯-2-氧代吡啶-1(2H)-基)-2-甲基-2-(甲基磺酰基)-丁酸(R2)
Smart Images

Figure CN119032080A_ABST
Abstract
Description
Technical Field
[0001] The present invention provides a novel method for preparing an LpxC hydroxamic acid inhibitor of the following formula (1) (i.e., (R)-4-(4-(4-(2H-1,2,3-triazol-2-yl)phenyl)-2-oxopyridine-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide).
[0002] Background Art
[0003] The LpxC inhibitor (R)-4-(4-(4-(2H-1,2,3-triazol-2-yl)phenyl)-2-oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)-butyramide (1) is a veterinary hydroxamic acid antibiotic that is bioactive against a variety of Gram-negative bacteria. Gram-negative bacteria cause a wide range of diseases, including infections associated with the urinary tract, bloodstream, gastrointestinal tract, and airways. Gram-negative bacteria have an asymmetric bilayer composed of the glycolipid lipopolysaccharide and glycerophospholipids, which constitute the bacterial outer membrane. The Gram-negative outer membrane is an important barrier that provides protection against antibiotics and host innate immune molecules (such as cationic antimicrobial peptides); and is an important construct that contributes to antimicrobial resistance. Recently, Gram-negative bacteria resistant to commonly used antibiotics including quinolones, colistin (polymyxin), carbapenems, cephalosporins, and other β-lactam antibiotics have been isolated from animals with increasing frequency. Since few new antibiotics targeting Gram-negative bacteria are being developed, and organisms that resist all or most clinically useful antimicrobial agents have been isolated, drug-resistant infections due to Gram-negative bacteria are a major health care concern in the future. Therefore, new antibiotics are needed for both susceptible and resistant Gram-negative bacteria.
[0004] Gram-negative bacteria such as Escherichia coli, Salmonella and Haemophilus parasuis have become a major problem for the swine industry over the years. Pathogens produced by these bacteria not only cause inflammation but also different diseases and make pigs more susceptible to viral infections. Different strains of E. coli can cause diarrhea and enterotoxemia in piglets, diseases that can lead to decreased weight gain or even sudden death. Salmonella enterica can cause both pneumonia and diarrhea in pigs and foodborne gastroenteritis in humans. Another important harmful pig bacterium, Haemophilus parasuis, is the cause of a condition known as Glasser's disease. disease), fibrinous polyserositis, meningitis, and arthritis.
[0005] In recent years, many genera and species of bacteria have begun to show some resistance to Gram-negative antibiotics. Therefore, there is a continuing need for new antibacterial agents to combat these bacteria, particularly resistant Gram-negative bacteria. LpxC inhibitors of formula (1) have shown antibacterial effects on Gram-negative bacteria. Previous citations describe this molecule and its preparation, namely U.S. Patent No. 8,664,401. However, the described method is not scalable because it only provides a yield of about 13% of the key enantiomerically pure intermediate (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-butyric acid (R2). In addition, this method describes the use of expensive (e.g., Cs2CO3) and dangerous (e.g., NaH) reagents, requires additional synthesis steps, and contains unstable intermediate 4-bromo-2-methyl-2-(methylsulfonyl)butyric acid ethyl ester. The method described herein provides a novel scalable process with fewer steps, stable intermediates, no hazardous or expensive reagents, and an overall yield of 31% for the (R2) intermediate. Summary of the invention
[0006] In view of the number of procedural steps and use of expensive and hazardous reagents to prepare relatively low yields of formula (1) as described in the art, a more robust and efficient method was developed to prepare higher and less expensive yields of compounds of formula (1).
[0007]
[0008] In one aspect of the present invention, the racemic intermediate compound is 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (rc1).
[0009]
[0010] In another aspect is a method for preparing 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (rc1) intermediate compounds according to the following rxn-1 procedure:
[0011]
[0012] The method comprises:
[0013] a) reacting 3-bromotetrahydrofuran-2(3H)-one (a) with sodium methanesulfinate in the presence of solvent A, a phase transfer catalyst and optionally a dehydrating agent at a temperature of about 40-100° C. for about 1-24 hours to prepare an intermediate 3-(methylsulfonyl)-dihydrofuran-2(3H)-one (b);
[0014] b) allowing the mixture to cool at ambient temperature overnight, filtering the solid, and washing the solid with solvent A;
[0015] c) reacting the solid with a base in the presence of a phase transfer catalyst, a methylating agent, a solvent B and optionally a dehydrating agent at a temperature of about 40-100° C. for a period of about 4-48 hours;
[0016] d) charging the reactor with additional methylating agent and base while heating for an additional 4 hours;
[0017] e) filtering the solid while retaining the solvent filtrate;
[0018] f) washing the solid with solvent B while again retaining the solvent filtrate, and then heating the combined filtrates to about 65° C. while distilling off all but about 1.5 volumes of the filtrate;
[0019] g) exchanging the solvent with solvent A, cooling and seeding; and
[0020] h) further cooling to induce crystallization, filtering the crystals, and washing the crystals with solvent A to obtain the final product, i.e. 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (rc1).
[0021] In another aspect, is a RXN-1 method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (RC1), the method comprising:
[0022] a) reacting 3-bromotetrahydrofuran-2(3H)-one with sodium methanesulfinate in the presence of isopropanol, a phase transfer catalyst and optionally a dehydrating agent at a temperature of about 50-80° C. for about 1-11 hours to prepare 3-(methylsulfonyl)dihydrofuran-2(3H)-one;
[0023] b) allowing the mixture to cool at ambient temperature overnight and filtering the solid and washing the solid with isopropanol;
[0024] c) reacting the solid with potassium carbonate in the presence of a phase transfer catalyst, dimethyl sulfate, acetone and optionally a dehydrating agent at a temperature of about 50-80° C. for a period of about 16-24 hours;
[0025] d) charging the reactor with additional dimethyl sulfate and potassium carbonate while heating for an additional 4 hours;
[0026] e) filtering the solid while retaining the acetone filtrate;
[0027] f) washing the solid with acetone while again retaining the acetone filtrate and heating to about 65° C. while distilling off all but about 1.5 volumes of the filtrate;
[0028] g) exchanging the acetone with isopropanol, cooling to about 35° C. and seeding; and
[0029] h) further cooling to about 25° C. to induce crystallization, filtering the crystals, and washing the crystals with isopropanol to obtain 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one.
[0030] In another aspect, is a RXN-1 method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (RC1), the method comprising:
[0031] a) reacting 3-bromotetrahydrofuran-2(3H)-one with sodium methanesulfinate in the presence of isopropanol, methyltrioctylammonium chloride and optionally a dehydrating agent, magnesium sulfate, at a temperature of about 80° C. for about 3 hours to prepare 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one;
[0032] b) allowing the mixture to cool at ambient temperature overnight, filtering the solid, washing the solid with isopropanol, and concentrating the solid;
[0033] c) reacting the solid with potassium carbonate in the presence of methyltrioctylammonium chloride, dimethyl sulfate, magnesium sulfate and isopropanol at a temperature of about 60° C. for about 7 hours;
[0034] d) charging the reactor with additional dimethyl sulfate and potassium carbonate while heating for an additional 4 hours;
[0035] e) filtering the reaction mixture to remove inorganic salts;
[0036] f) washing the solid with acetone and heating to about 65° C. while distilling off all but about 1.5 volumes of the filtrate;
[0037] g) exchanging the acetone with isopropanol, cooling the mixture to about 35° C., and seeding the mixture; and
[0038] h) further cooling to about 25° C. to induce crystallization, filtering the crystals, and washing the crystals with isopropanol to obtain 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one.
[0039] In another aspect, is a RXN-1 method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (RC1), the method comprising:
[0040] a) reacting 3-bromotetrahydrofuran-2(3H)-one with sodium methanesulfinate in the presence of isopropanol, methyltrioctylammonium chloride and magnesium sulfate at a temperature of about 80° C. for about 3 hours to prepare an intermediate 3-(methylsulfonyl)dihydrofuran-2(3H)-one;
[0041] b) allowing the mixture to cool overnight at ambient temperature and isolating the solid by dissolving in isopropanol, filtering the solid, and washing the solid with isopropanol;
[0042] c) reacting the solid with potassium carbonate in the presence of methyltrioctylammonium chloride, dimethyl sulfate and magnesium sulfate in acetone at a temperature of about 60° C. for about 7 hours;
[0043] d) charging the reactor with additional dimethyl sulfate and potassium carbonate while heating for an additional 4 hours;
[0044] e) filtering the solid while retaining the acetone filtrate;
[0045] f) washing the solid with acetone while again retaining the acetone filtrate and then heating the combined filtrates to about 65° C. while distilling off all but about 1.5 volumes of the filtrate;
[0046] g) exchanging the acetone with isopropanol and cooling the mixture to about 35° C. and seeding; and
[0047] h) further cooling to about 25° C. to induce crystallization, filtering the crystals, and washing the crystals with isopropanol to obtain 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one.
[0048] In another aspect, is a telescoping method (rxn-t) for preparing the intermediate compound 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (rc1) according to the following telescoping procedure:
[0049]
[0050] The method comprises:
[0051] a) reacting 3-bromodihydrofuran-2(3H)-one (a) with sodium methanesulfinate in the presence of a phase transfer catalyst, solvent B and optionally a dehydrating agent in a jacketed reactor at 50-80° C. for about 7-11 hours;
[0052] b) allowing the mixture to cool to room temperature while stirring overnight for about 12 hours; filtering the reaction mixture, retaining the filtrate, and washing the solid with solvent B while retaining the filtrate;
[0053] c) reacting the combined filtrates with a methylating agent, a base and optionally a dehydrating agent while slowly heating the reactants to about 50-80° C. for about 15-20 hours;
[0054] d) adding more base and methylating agent to the mixture and heating for an additional approximately 3-6 hours;
[0055] e) cooling the mixture to ambient temperature and filtering to remove solids while retaining the filtrate;
[0056] f) washing the solid with solvent B while again retaining the filtrate and heating the combined filtrates to about 60-70° C. and then distilling off the solvent while retaining about 1.5 volumes; and
[0057] g) exchanging solvent B with solvent A while cooling to about 30-40°C and seeding; then further cooling to about 20-25°C to give 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one.
[0058] In another aspect, is an RXN-T method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (RC1), the method comprising:
[0059] a) reacting 3-bromodihydrofuran-2(3H)-one with sodium methanesulfinate in the presence of a phase transfer catalyst, a dehydrating agent and acetone in a jacketed reactor at 50-80° C. for about 7-11 hours;
[0060] b) allowing the mixture to cool to room temperature while stirring overnight for about 12 hours; filtering the reaction mixture and retaining the filtrate, washing the solid with acetone and again retaining the filtrate;
[0061] c) reacting the filtrate with dimethyl sulfate, a base and a dehydrating agent while slowly heating the reactants to about 50-80° C. for about 15-20 hours;
[0062] d) adding more base and methylating agent to the mixture and heating for an additional about 3-6 hours;
[0063] e) cooling the mixture to ambient temperature and filtering to remove solids while retaining the filtrate;
[0064] f) washing the solid with acetone and again retaining the filtrate and heating the combined filtrates to about 60-70° C. and then distilling off the acetone while again retaining about 1.5 volumes; and
[0065] g) exchanging the acetone with isopropanol while cooling to about 30-40° C. and seeding; and then further cooling to about 20-25° C. to obtain 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one.
[0066] In another aspect, is an RXN-T method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (RC1), the method comprising:
[0067] a) reacting 3-bromodihydrofuran-2(3H)-one with sodium methanesulfinate in the presence of methyltrioctylammonium chloride, magnesium sulfate and acetone in a jacketed reactor at about 56° C. to reflux for about 9 hours;
[0068] b) allowing the mixture to cool to room temperature while stirring overnight for about 12 hours; filtering the reaction mixture while retaining the filtrate and washing the solid with acetone, again retaining the filtrate;
[0069] c) reacting the combined filtrates with dimethyl sulfate, anhydrous potassium carbonate and anhydrous magnesium sulfate while slowly heating the reactants to reflux at about 56° C. for about 15 hours;
[0070] d) adding more potassium carbonate and dimethyl sulfate to the mixture and heating for about an additional 4 hours;
[0071] e) cooling the mixture to ambient temperature and filtering to remove solids while retaining the filtrate;
[0072] f) washing the solid with acetone and again retaining the filtrate and heating the combined filtrates to about 65° C. and then distilling off the acetone while again retaining about 1.5 volumes; and
[0073] g) exchanging the acetone with isopropanol while cooling to about 35°C and seeding; and then further cooling to about 20°C to obtain 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one.
[0074] In another aspect, the reactants for preparing the intermediate compound 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (rc1) from 3-bromodihydrofuran-2(3H)-one include the following: a preferred base is selected from the group consisting of potassium carbonate, sodium carbonate, potassium phosphate and cesium carbonate; a preferred methylating agent is selected from the group consisting of iodomethane, methyl bromide, methyl chloride, dimethyl sulfate and dimethyl carbonate; a preferred phase transfer catalyst is selected from the group consisting of methyltrioctylammonium chloride, PEG 300 and PEG 400; a preferred dehydrating agent is selected from the group consisting of magnesium sulfate, sodium sulfate and calcium chloride; a preferred solvent A is selected from the group consisting of isopropanol, ethanol, methanol and acetonitrile; and a preferred solvent B is acetone or 2-butanone.
[0075] In another aspect, the reactants for preparing the intermediate compound 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one from 3-bromodihydrofuran-2(3H)-one include the following: a more preferred base is potassium carbonate, a more preferred methylating agent is dimethyl sulfate, a more preferred phase transfer catalyst is methyltrioctylammonium chloride, a more preferred dehydrating agent is magnesium sulfate, a more preferred solvent A is isopropanol, and a more preferred solvent B is acetone.
[0076] In another aspect, a method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (rc1) from 3-(methylsulfonyl)dihydrofuran-2(3H)-one (b) and a dehydrating agent using potassium carbonate as a base, dimethyl sulfate as a methylating agent, and acetone as a solvent B. In another aspect, a method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (rc1) from 3-(methylsulfonyl)dihydrofuran-2(3H)-one (b) and a dehydrating agent using sodium carbonate as a base, methyl iodide as a methylating agent, and acetonitrile as a solvent B. In another aspect, a method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (rc1) from 3-(methylsulfonyl)dihydrofuran-2(3H)-one (b) and a dehydrating agent using potassium carbonate as a base, methyl iodide as a methylating agent and acetone as a solvent B. In another aspect, a method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (rc1) from 3-(methylsulfonyl)dihydrofuran-2(3H)-one (b) and a dehydrating agent using potassium carbonate as a base, methyl iodide as a methylating agent and acetone as a solvent B. In another aspect, a method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (rc1) from 3-(methylsulfonyl)-dihydrofuran-2(3H)-one (b) and a dehydrating agent using sodium carbonate as a base, iodomethane as a methylating agent, and acetone as a solvent B. In another aspect, a method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (rc1) from 3-(methylsulfonyl)-dihydrofuran-2(3H)-one (b) and a dehydrating agent using potassium phosphate as a base, iodomethane as a methylating agent, and acetone as a solvent B. In another aspect, a method for preparing the intermediate compound 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (rc1) from 3-(methylsulfonyl)dihydrofuran-2(3H)-one (b) and a dehydrating agent using sodium carbonate as a base, methyl iodide as a methylating agent, and 2-butanone as a solvent B.
[0077] In another aspect, a method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (rc1) from 3-(methylsulfonyl)-dihydrofuran-2(3H)-one (b) using potassium carbonate as a base, dimethyl sulfate as a methylating agent and acetone as a solvent B in the absence of a dehydrating agent. In another aspect, a method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (rc1) from 3-(methylsulfonyl)-dihydrofuran-2(3H)-one (b) using sodium carbonate as a base, methyl iodide as a methylating agent and acetonitrile as a solvent B in the absence of a dehydrating agent. In another aspect, a method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (rc1) from 3-(methylsulfonyl)dihydrofuran-2(3H)-one (b) using potassium carbonate as a base, methyl p-toluenesulfonate as a methylating agent and acetone as a solvent B in the absence of a dehydrating agent. In another aspect, a method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (rc1) from 3-(methylsulfonyl)dihydrofuran-2(3H)-one (b) using potassium carbonate as a base, methyl iodide as a methylating agent and acetone as a solvent B in the absence of a dehydrating agent. In another aspect, a method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (rc1) from 3-(methylsulfonyl)-dihydrofuran-2(3H)-one (b) using sodium carbonate as a base, iodomethane as a methylating agent and acetone as solvent B in the absence of a dehydrating agent. In another aspect, a method for preparing an intermediate compound 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (rc1) from 3-(methylsulfonyl)-dihydrofuran-2(3H)-one (b) using potassium phosphate as a base, iodomethane as a methylating agent and acetone as solvent B in the absence of a dehydrating agent. In another aspect, a method for preparing the intermediate compound 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (rc1) from 3-(methylsulfonyl)dihydrofuran-2(3H)-one (b) using sodium carbonate as a base, methyl iodide as a methylating agent, and 2-butanone as a solvent B in the absence of a dehydrating agent.
[0078] In another aspect of the present invention is an enantiomerically pure intermediate compound (R)-3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (R1).
[0079]
[0080] In another aspect is a method for preparing enantiomerically pure intermediate compound (R1) from racemic (rc1) substrate using chiral chromatography according to the following procedure.
[0081]
[0082] In another aspect, chiral separation of the enantiomerically pure intermediate compound (R1) from the racemic substrate (rc1) can be accomplished by chiral chromatography. In another aspect, the chiral chromatography uses Column or In another aspect, the The chromatographic column is an AD column, an AS column, an AY column, an AZ column, an IA column, an IB column, an IC column, an ID column, an IE column, an IF column or an IG column. The column is AD In another aspect, the AD chromatographic column separates the enantiomerically pure intermediate compound (R1) from the racemic (rc1) substrate. In another aspect, the The column is OD or OJ In another aspect, the OD or OJ chromatographic column to separate the enantiomerically pure intermediate compound (R1) from the racemic (rc1) substrate. In another aspect, OD column to separate the enantiomerically pure intermediate compound (R1) from the racemic (rc1) substrate. In another aspect, The OJ column separates the enantiomerically pure intermediate compound (R1) from the racemic (rc1) substrate.
[0083] In another aspect, is a method for preparing an intermediate compound (rc2) from (rc1) according to the following procedure: reacting (rc1) with a pyridone in the presence of a base and a solvent to prepare (rc2):
[0084]
[0085] In another aspect, a method for preparing an intermediate compound 4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (rc2) from 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (rc1) is provided, the method comprising:
[0086] a) dissolving potassium tert-butoxide in anhydrous DMSO and then adding 4-chloropyridin-2(1H)-one while maintaining the temperature between about 18-27°C;
[0087] b) adding to a mixture of (rc1) and benzyltriethylammonium bromide and heating to about 85° C. for about 2 hours;
[0088] c) aging the reaction at about 85° C. for about 17-20 hours;
[0089] d) adding isopropyl acetate and stirring at about 60° C. for about 1 hour;
[0090] e) cooling to about 20° C. within one hour and aging for one hour; filtering the solid, washing with isopropyl acetate, and drying at about 50° C. overnight to produce the potassium salt of (rc2);
[0091] f) dissolving the dried solid in water, treating with methanol and methyltetrahydrofuran, and charging with concentrated HCl;
[0092] g) stirring the slurry at room temperature for about 2 hours and cooling to about 0-5° C. while stirring for another hour;
[0093] h) The slurry was filtered and washed with water:MeOH (8:2) and then dried in vacuo under nitrogen to give (rc2).
[0094] In another aspect, a method for preparing an intermediate compound 4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (rc2) from 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (rc1) is provided, the method comprising:
[0095] a) charging a reactor with PEG, 2-methyl-2-butanol and 4-chloro-2-hydroxypyridine under nitrogen;
[0096] b) adjusting the reactor temperature to about 18-25° C. and adding potassium tert-butoxide while stirring;
[0097] c) aging the reaction mixture at about 40-50° C. for about 30-60 minutes;
[0098] d) adding (rc1) to the reactor and heating to about 100° C. within about 15-30 minutes;
[0099] e) maintaining the temperature at about 95-100° C. for about 12-24 hours;
[0100] f) cooling the reaction to about 50-60° C., diluting with water, and adjusting the pH to about 1-2 with HCl;
[0101] g) cooling the reactants to about 0-5° C. over about 1-3 hours, aging for about 1-2 hours, and filtering the resulting solids; and
[0102] h) washing the solid with water and drying to obtain (rc2).
[0103] In another aspect, a method for preparing an intermediate compound 4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (rc2) from 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (rc1) is provided, the method comprising:
[0104] a) charging a reactor with PEG 400, 2-methyl-2-butanol and 4-chloro-2-hydroxypyridine under nitrogen;
[0105] b) adjusting the reactor temperature to about 20° C. and adding potassium tert-butoxide portionwise while stirring;
[0106] c) aging the reaction mixture at about 40-45° C. for about 30-45 minutes;
[0107] d) adding (rc1) to the reactor and heating to about 100° C. within about 20 minutes;
[0108] e) maintaining the temperature at about 95-100° C. for about 16-20 hours;
[0109] f) cooling the reaction to about 50-60° C., diluting with water, and adjusting the pH to about 1-2 with HCl;
[0110] g) cooling the reaction to 0° C. over about 2 hours, aging for about 1 hour, and filtering the resulting solid; and
[0111] h) washing the solid with deionized water and drying at about 70° C. to obtain (rc2).
[0112] In another aspect, is an intermediate compound 4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (rc2).
[0113] In another aspect is a method for preparing the intermediate compound (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (R2) from enantiomerically pure (R)-3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (R1) according to the following procedure:
[0114]
[0115] (R1) is reacted with a pyridone in a solvent to prepare (R2); wherein R' is H or K.
[0116] In another aspect, is a method for preparing the intermediate compound (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (R2) from (R)-3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (R1), the method comprising:
[0117] a) dissolving potassium tert-butoxide in anhydrous DMSO or sulfolane and then adding 4-chloropyridin-2(1H)-one while maintaining the temperature between about 18-27°C;
[0118] b) adding to a mixture of (R)-3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (R1) and benzyltriethylammonium bromide and heating to about 85° C. for 2 hours;
[0119] c) aging the reaction at about 85° C. for about 17-20 hours;
[0120] d) adding isopropyl acetate and stirring at about 60° C. for about 1 hour;
[0121] e) cooling to about 20° C. over one hour and aging for one hour; filtering the solid, washing with isopropyl acetate, and drying at about 50° C. overnight to produce the potassium salt of (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid;
[0122] f) dissolving the dried solid in water, treating with methanol and methyltetrahydrofuran, and charging with concentrated HCl;
[0123] g) stirring the slurry at room temperature for about 2 hours and cooling to about 0-5° C. while stirring for an additional hour; and
[0124] h) The slurry was filtered and washed with water:MeOH (8:2) and then dried in vacuo under nitrogen to give (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid.
[0125] In another aspect is an intermediate compound (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (R2).
[0126] In another aspect is an (S)-enantiomerically pure intermediate compound (S1) 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one.
[0127] BRIEF DESCRIPTION OF THE DRAWINGS
[0128] Figure 1 : Powder X-ray diffraction patterns of Form 1, Form 2 and Form 3 of the compound of formula (1) (R)-4-(4-(4-(2H-1,2,3-triazol-2-yl)phenyl)-2-oxopyridine-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)-butyramide. DETAILED DESCRIPTION
[0129] For purposes of the present invention, as described and claimed herein, the following terms and phrases are defined as follows:
[0130] When used in conjunction with a measurable numerical variable, "about" refers to the indicated value of the variable and all values of the variable that are within the experimental error range of the indicated value (e.g., within a 95% confidence interval for the mean) or within 10% of the indicated value, whichever is greater. As a descriptor, the term can be easily removed.
[0131] As used herein, unless otherwise indicated, "animal" refers to an individual animal that is a mammal. Specifically, mammal refers to a non-human vertebrate that is a member of the taxonomic class Mammalia. Examples of non-human mammals include companion animals (i.e., cats, dogs, and horses) and livestock (i.e., pigs, cattle, sheep, and goats). Preferred livestock are pigs and cattle; more preferred are pigs.
[0132] As used herein, unless otherwise indicated, "pharmaceutically acceptable" indicates that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients comprising the composition (formulation) and / or the animal to be treated. The use of the phrase "and a pharmaceutically acceptable salt" is interchangeable with the use of "or a pharmaceutically acceptable salt".
[0133] As used herein, unless otherwise indicated, "seeding" means adding a small sample of crystals or polycrystalline material (e.g., a reference standard) of the final intermediate or product to be obtained from a reaction to a supersaturated reaction mixture to promote the growth of the desired crystals, thereby enhancing the intermolecular forces between the individual molecules in the solution to form the basis of the crystal lattice and eliminating the need for random molecular collisions or interactions.
[0134] As used herein, the following intermediates (compounds) and their corresponding names are synonymous:
[0135] (a) = 3-bromodihydrofuran-2(3H)-one;
[0136] (b) = 3-(methylsulfonyl)dihydrofuran-2(3H)-one;
[0137] (rc1) = 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (racemic);
[0138] (rc2) = 4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (racemic);
[0139] (R1) = (R) -3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one;
[0140] (R2) = (R) -4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-butanoic acid, and
[0141] (S1) = (S) -3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one.
[0142] LpxC inhibitor (Formula (1)) (R)-4-(4-(4-(2H-1,2,3-triazol-2-yl)phenyl)-2-oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)-butyramide is a veterinary hydroxamic acid antibiotic that has biological activity against various Gram-negative bacteria. The compound can be formulated as a free base with at least one other pharmaceutically acceptable excipient or as a salt with at least one other pharmaceutically acceptable excipient. For the purpose of this method, the hydroxamic acid compound of formula (1) can be formulated for use in treating Gram-negative bacteria in livestock (i.e., cattle and pigs; and preferably pigs).
[0143] Racemic intermediate compound (rc1) has chiral center, and therefore comprises the racemic mixture of two enantiomers.Except being able to make plane polarized light (+ / -) rotate with equal amount but in opposite directions, each enantiomer has identical chemical and physical properties.Enantiomer is also referred to as optical isomer.The plane polarized light of the mixture of equal parts of optically active isomer and its enantiomer is zero net rotation, because the positive rotation of each (+) form is just offset by the negative rotation of each (-) form.Can complete separation (R1) enantiomer from racemic mixture by standard chromatographic method on chiral adsorbent.Alternately, racemate can be coupled with reactant (c), to prepare (rc2), described (rc2) can be split into (R2) by classical resolution technique by making (rc2) react with optically pure (S)-(+)-α-methylbenzylamine.
[0144] Medicinal salt
[0145] The compound of formula (1) can be used in its natural form (base) or as a salt. The compound of formula (1) has a basic functional group and can form an addition salt with an acid. Such salts are included within the scope of the present invention to the extent acceptable for veterinary use. Suitable acid addition salts are formed from acids that form non-toxic salts. Examples include acetate, adipate, aspartate, benzoate, benzenesulfonate, bicarbonate / carbonate, bisulfate / sulfate, borate, camphorsulfonate, citrate, cyclamate, edisylate, ethanesulfonate, formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, lactate, malate, maleate, malonate, methanesulfonate, methylsulfate, naphthoate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, p-toluenesulfonate, trifluoroacetate, and xinafoate.
[0146] Composition / Formulation
[0147] Pharmaceutical compositions comprising compounds of formula (1) can be manufactured by processes well known in the art, for example, by conventional mixing, dissolving, granulating, levigating, emulsifying, encapsulating, embedding, lyophilizing processes or spray drying.
[0148] The pharmaceutical composition used according to the compound of formula (1) can be formulated in a conventional manner using one or more pharmaceutically acceptable excipients, which facilitate the processing of the active compound into a preparation that can be used for drug administration to animals in need. The appropriate formulation depends on the selected route of administration. Pharmaceutically acceptable excipients are generally known to those skilled in the art and are therefore included in the present invention. Such excipients are generally described in, for example, Remington's Pharmaceutical Sciences, Mack Pub. Co., New Jersey (1991). In one aspect, the composition including the compound of formula (1) is prepared as an oral, parenteral (intravenous, intramuscular and subcutaneous) or topical composition. The preferred route of administration is oral administration, and is specifically used for administration in drinking water. The preferred animals to receive the composition are livestock, preferably cattle and pigs. Most preferably, pigs. Oral compositions can be formulated with other excipients. Other commonly used excipients for preparing pharmaceutical compositions may include, for example, any one or more of the following: antioxidants (e.g., BHT, BHA, vitamin E, sodium metabisulfite, propyl gallate, etc.); preservatives (e.g., benzyl alcohol, citric acid, alkyl parabens, phenol, metacresol, etc.); defoaming agents (e.g., cetearyl alcohol, castor oil, stearate, polydimethylsiloxane, ethylene glycol, etc.); surfactants (e.g., polysorbate, sodium lauryl sulfate, lauryl dimethylamine oxide, polyethoxylated alcohol, polyoxyethylene sorbitan, octoxynol, polyoxyl 10 lauryl ether, polyoxy castor oil, cyclodextrin, lecithin, etc.); and hydrotropes (e.g., niacinamide, benzamide, N,N-diethyl niacinamide, nicotinic acid, sodium benzoate, urea, potassium salicylate or sodium salicylate, etc.), which can improve the water solubility of the compound of formula (1). The compound of formula (1) can be prepared in concentrated amounts, such as 10 mg / mL, 25 mg / mL, 50 mg / mL, 100 mg / mL, 150 mg / mL, 200 mg / mL, 250 mg / mL and higher. The compound of formula (1) can be administered to an animal in need at a dosage ranging from about 0.25 mg / kg to about 2.5 mg / kg; or a dosage ranging from about 0.5 mg / kg to about 2 mg / kg; or a dosage ranging from about 0.75 mg / kg to about 1.5 mg / kg; or a dosage ranging from about 1 mg / kg to about 1.25 mg / kg. The compound of formula (1) can be administered to an animal in need at a dosage ranging from 0.25 mg / kg to 2.5 mg / kg; or a dosage ranging from 0.5 mg / kg to 2 mg / kg; or a dosage ranging from 0.75 mg / kg to 1.5 mg / kg; or a dosage ranging from 1 mg / kg to 1.25 mg / kg.
[0149] Veterinary use
[0150] The compounds of formula (1) can be used to treat or prevent infectious conditions, especially infectious conditions caused by susceptible and multi-drug resistant Gram-negative bacteria in animals. Non-limiting examples of such Gram-negative bacteria include Acinetobacter baumannii, Acinetobacter spp., Achromobacter spp., Aeromonas spp., Actinobacillus pleuropneumoniae, Bacteroides fragilis, Bordetella spp., Borrelia spp., Brucella spp., Campylobacter spp., Citrobacter diversus (koseri), Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Francisella tularensis, tularensis), Fusobacterium spp., Haemophilus parasuis, Helicobacter pylori, Klebsiella oxytoca, Klebsiella pneumoniae, Lawsonia intracellularis, Legionella pneumophila, Moraxella catarrhalis (β-lactamase positive and negative), Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus vulgaris, Porphyromonas spp., Prevotella spp., Mannheimia haemolyticus, Pasteurella spp.), Proteus mirabilis, Providencia spp., Pseudomonas aeruginosa, Pseudomonas spp., Salmonella spp. (S. enterica), Shigella spp., Serratia marcescens, Treponema spp., Burkholderia cepacia, Vibrio spp., Yersinia spp., and Stenotrophomonas mulophilia.
[0151] Examples of infections that can be treated with compounds of formula (1) include nosocomial pneumonia, urinary tract infections, systemic infections (bacteremia and sepsis), skin and soft tissue infections, lung infections, surgical infections, intra-abdominal infections, etc. A preferred use of compounds of formula (1) is the treatment of animals, preferably livestock (e.g., cattle and pigs), and more preferably pigs, against Gram-negative bacteria.
[0152] Examples
[0153] The following abbreviations described herein include: ethanol (EtOH); isopropanol (IPA); methyl (Me); ethyl (Et); ethyl acetate (EtOAc), potassium acetate (KOAc), sodium hydride (NaH); methanol (MeOH); sodium carbonate (Na2CO3); polyethylene glycol (PEG); hydrochloric acid (HCl); acetonitrile (MeCN, CH3CN, Acn); potassium carbonate (K2CO3); oxalyl chloride (CsO2Cl2); potassium phosphate (K3PO4), methyl trifluoromethanesulfonate (MeOTf); methyl p-toluenesulfonate (MeOTs); dimethyl sulfate ((CH3)2SO4); cesium carbonate (Cs2CO3); trifluoroacetic acid (TFA); tetrahydrofuran (THF); calcium oxide (CaO); potassium hydroxide (KOH); sodium hydroxide (NaOH); sodium bromide (NaBr); dichloromethane (DCM); tetrahydrofuran (THF); THP; potassium acetate (KOAc); potassium tert-butoxide (KOtBu); sodium borohydride (NaBH4); hydrobromic acid (HBr); aluminum oxide (Al2O3); 2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl (XPhos); magnesium sulfate (MgSO4); sodium sulfate (Na2SO4); calcium chloride (CaCl2); methyl iodide (MeI); dimethyl sulfoxide ( DMSO); methyl bromide (MeBr); methyl chloride (MeCl); methyl lithium (MeLi); butylated hydroxytoluene (BHT); butylated hydroxyanisole (BHA); dibromoethane (DBE); lithium hydroxide (LiOH); chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) second generation (XPhos PD G2); tetrahydroxydiboron (B2(OH)4); sodium methanesulfinate (MeSO2Na); aqueous solution (aq); equivalent (eq); not more than (NMT); not less than (NLT); catalyst (cat); limit of detection (LOD); volume (vol); minute (min); melting point (mp); and room temperature (RT).
[0154] Schemes 1-3 outline the general procedures for preparing and separating (or not separating (i.e., telescoping)) intermediate compounds (b), (rc1), (R1), (rc2), (R2) and compounds of formula (1). However, it should be understood that the present invention is not intended to be limited by the details of the following preparation schemes or patterns, as fully described herein and described in the claims. Starting materials and various reactants can be readily prepared from commercially available organic compounds, either from commercial sources or using methods well known to those skilled in the art.
[0155] Alternatively, the intermediate compound (R2) and the compound of formula (1) can be prepared by the method described in U.S. Pat. No. 8,664,401 and PCT Publication WO2019178305. The method for preparing the intermediate compound (R2) using the method described herein has many advantages over existing methods, such as:
[0156] 1) For the chiral resolution pathway and the classical resolution pathway, the step count of (R2) is 4 or 6, respectively, instead of 7 steps;
[0157] 2) using the novel lactone intermediate (rc1) to eliminate the unstable intermediate 4-bromo-2-methyl-2-(methylsulfonyl)butyric acid ethyl ester;
[0158] 3) The yield increased more than 2-fold, from 13% to 31% (maximum 50%);
[0159] 4) Improve scalability by eliminating expensive (Cs2CO3) and hazardous (NaH) reagents; and
[0160] 5) Potential for telescoping (non-isolated) reaction steps.
[0161] Scheme 1: Preparation of intermediate (R2)
[0162]
[0163] As shown in scheme 1, commercial α-bromo-γ-butyrolactone (a) and the treatment of sodium methanesulfinate are obtained sulfone (b), and according to the solvent used, the sulfone can be separated or [overlapped] in the next step. (b) is exposed to alkali (for example, sodium carbonate, potassium carbonate, etc.) in the presence of a methylating agent (for example, methyl iodide, dimethyl sulfate, etc.) to produce (rc1). Carboxylic acid (R2) is realized by two different approaches, one approach depends on classical resolution, and another approach depends on chiral chromatography resolution. In the presence of alkali (for example, potassium tert-butoxide, sodium tert-amyl alcohol, etc.), pyridone (c) [wherein R ' is H or K] is used to alkylate lactone (rc1) to obtain (rc2). Use chiral amine (for example, α-methylbenzylamine, ephedrine, phenylglycinol, etc.) to realize the classical resolution of (rc2), so as to obtain (R2) in the form of single enantiomer.
[0164] Alternatively, (rc1) chromatographic separation obtains (R1) in single enantiomeric form. According to methods known in the art (Geoffrey B. Cox preparative enantioselective chromatography (Cox Preparative Enantioselective Chromatography), Blackwell Publishing Co., Ltd. (Blackwell Publishing, Ltd): Ames, Iowa (Ames, IA); 2005) use chiral stationary phase (for example, ChiralPak AD, Chiralcel OJ etc.) and the mobile phase consisting of suitable HPLC solvent (for example, methanol, ethanol, isopropanol, heptane, methyl tert-butyl ether etc.) to carry out chromatography. In the presence of alkali (for example, potassium tert-butoxide, sodium tert-amyl alcohol etc.), lactone (R1) is alkylated with pyridone (c) to obtain (R2).
[0165] Scheme 2: Preparation of compounds of formula (1) from (R2)
[0166]
[0167] Analogs (2.1) are obtained by palladium catalyzed Suzuki cross coupling of pyridone chloride (R2) and borocyclopentane (d) as described in Scheme 2. Alternatively, 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2H-1,2,3-triazole can be used instead of (d). Carboxylic acid (2.1) is converted to the corresponding acid chloride (2.2) using typical reagents known in the art (such as oxalyl chloride, thionyl chloride, etc.). The acid chloride (2.2) is subjected to tetrahydropyranyl protected hydroxylamine to obtain intermediate (2.3). The tetrahydropyranyl group is cleaved using typical reagents known to those skilled in the art (e.g., aqueous acids (e.g., hydrochloric acid, sulfuric acid, maleic acid, phosphoric acid, oxalic acid, citric acid, tartaric acid, methanesulfonic acid, p-toluenesulfonic acid, pyridine p-toluenesulfonate, etc.) to obtain a compound of formula (1). Preferred cleavage reagents are sulfuric acid or maleic acid. Additional chemical descriptions of this process can be found in U.S. Patent No. 8,664,401 and PCT Publication WO2019 / 178305.
[0168] Scheme 3 – Historical preparation of (R2)
[0169]
[0170] According to scheme 3, 2-chloropropionic acid ethyl ester is treated with sodium methanesulfinate and then exposed to sodium hydride and ethylene dibromide to obtain bromide. According to literature procedure (Honraedt and Gallagher "Synthetic Chemistry Express (SynLett)", 2016, 27, 67), chloropyridone is alkylated with bromide in the presence of cesium carbonate and then ester is saponified with lithium hydroxide to produce (rc2). According to known known procedures (i.e. Brown et al., "Journal of Medicine (J.Med.Chem.)" 2021, 55, 914), (-)-ephedrine is used to carry out classical separation of (rc2), to obtain (R2) in the form of a single enantiomer.
[0171] As described herein, enantiomerically pure enantiomers (R1) can be separated from racemic mixtures (rc1) or substrates by chiral chromatography techniques. For example, AD, AS, AY, AZ, IA, IB, IC, ID, IE, IF, IG column or OD or OJ column; both use a solvent mobile phase selected from any one of the following: methanol, ethanol, isopropanol, acetonitrile, acetone, ethyl acetate, THF, CH2Cl2, MTBE and heptane or a mixture thereof. Preferred HPLC solvents are selected from methanol, ethanol and heptane. The most preferred HPLC solvent is methanol.
[0172] The preferred column for separating the (R1) enantiomer from the racemate (rc1) is AD. The column is packed with a coated polysaccharide-based chiral stationary phase prepared by physically coating a polysaccharide derivative onto a silica matrix. The chromatographic separation is performed at a temperature of about 20-40°C, preferably about 20-35°C and more preferably about 25°C.
[0173] Non-limiting bases that can be used to prepare (R2) from intermediate (b) include, for example, Na2CO3, K2CO3, Cs2CO3, K3PO4, alkali metal tert-butoxide (e.g., potassium tert-butoxide, lithium tert-butoxide, sodium tert-butoxide, and rubidium tert-butoxide), sodium tert-amylate, etc. A preferred base is K2CO3, Na2CO3, or K3PO4; and a more preferred base is K2CO3.
[0174] Methylation means adding a methyl group to a substrate, i.e., alkylation form; replacing an H atom with a methyl group. Non-exclusive methylating agents include, for example, methyl iodide (CH3I), methyl bromide (CH3Br), methyl chloride (CH3Cl), methyl lithium (CH3Li), diazomethane, dimethyl carbonate, dimethyl dicarbonate, dimethyl sulfate, 1,2-dimethylhydrazine, dimethyl zinc, methyl fluorosulfinate, methylcobalamin, methylmagnesium chloride, trimethyl phosphate, methyl p-toluenesulfonate, methyl methanesulfonate, N-methyl-N'-nitrosoguanidine, etc. Preferred methylating agents are selected from dimethyl sulfate, methyl bromide and methyl iodide. The most preferred methylating agent is dimethyl sulfate.
[0175] Non-exclusive examples of organic solvents (solvents) include, for example, alcohols (ROH), wherein R is a linear, branched or cyclic alkyl group having 1 to 8 carbon atoms (e.g., methanol, ethanol, propanol, isopropanol, n-propanol, 2-butanol, n-butanol, tert-butanol, isobutanol, cyclopentanol, phenol, benzyl alcohol, etc.); nitrenes (e.g., acetonitrile, propionitrile, butyronitrile, isobutyronitrile, 2-methylbutyronitrile, valeronitrile, etc.); ketones (e.g., acetone, butanone, pentanenitrile, etc.); ketone, 2-methylpentanone, etc.); ethers (e.g., methoxymethane, methoxyethane, ethoxyethane, ethyl ether, diethyl ether, tetrahydrofuran, methoxybenzene, etc.); esters (e.g., ethyl acetate, methyl formate, methyl acetate, ethyl propionate, isopropyl butyrate, ethyl benzoate, etc.); dimethyl sulfoxide (DMSO), sulfolane, 3-methylsulfolane, dimethylformamide, dimethylacetamide, ethylene glycol, pyridine, toluene, dioxane, etc. Preferred solvents include isopropanol, acetone, acetonitrile, 2-butanol, sulfolane, tert-butanol and DMSO. More preferred solvents are isopropanol, acetone, 2-butanol, acetonitrile and sulfolane. Preferred solvent A is isopropanol, ethanol, methanol and acetonitrile. More preferred solvent A is isopropanol. Preferred solvent B is acetone or 2-butanone. More preferred solvent B is acetone.
[0176] Phase transfer catalyst is used to realize reaction between organic compound soluble in organic solvent (solvent) and water-soluble compound (such as inorganic salt) in heterogeneous system. Phase transfer catalyst is soluble in two kinds of solvents, and it brings the negative ion of inorganic salt into organic solvent (solvent) and makes the negative ion return to aqueous phase. Reaction is usually carried out by easy inspection procedure under mild conditions. For this reason, the phase transfer catalyst is also used in industry. Typical phase transfer catalyst comprises polyethylene glycol (PEG), quaternary ammonium salt, crown ether and phosphonium compound. Some non-exclusive examples of phase transfer catalyst include for example PEG 400, PEG 300, benzyl triethyl ammonium chloride, methyl tricaprylyl ammonium chloride, methyl tributyl ammonium chloride, tetrabutyl ammonium thiocyanate, tetrabutyl phosphonium bromide, methyl trioctyl ammonium chloride ( 336), tetrabutylammonium bromide, methyltrioctylammonium bromide, etc. Preferred phase transfer catalysts are PEG 400 and 336. 336 is a methyltrialkylammonium salt with C8 and C10 alkyl groups [(C(8 and 10)3NMe]. The Aliquat trademark is a registered trademark of Henkel Corporation, USA.
[0177] Dehydrating agents may also be used in the reactions described herein to dry and remove water. Non-exclusive examples of dehydrating agents include: MgSO4, Na2SO4, CaCL2, zinc chloride, NaBH4, Al2O3, calcium oxide (CaO), silica gel, and sieves. A preferred dehydrating agent is MgSO4.
[0178] Using a resolving agent is for reacting the racemic mixture of a compound with a single enantiomer of a chiral reagent called a resolving agent to convert the racemic mixture into a mixture of diastereomers, separating the components of the mixture of diastereomers, and chemically converting each diastereomer into the common resolution method of corresponding enantiomers. The non-exclusive resolving agent for classical resolution of (rc2) into (R2) comprises, for example, (S)-methylbenzylamine, phenylglycinol, ephedrine, cinconidine, 2-amino-1,2-diphenylethanol, quinine, quinidine, etc. Preferred resolving agents are (S)-methylbenzylamine and phenylglycinol. Most preferred resolving agent is (S)-methylbenzylamine.
[0179] Examples
[0180] Protons were collected at ambient temperature on a Bruker Avance III 600 MHz spectrometer or a Bruker Avance III HD 400 MHz spectrometer, each with a 5 mm broadband probe ( 1 H) Nuclear magnetic resonance (NMR) spectroscopy. Chemical shifts are reported in parts per million (δ) relative to tetramethylsilane (δ = 0.0) and referenced to residual solvent resonances (CDCl3 δ = 7.27 and DMSO-d6 δ = 2.50).
[0181] The lactone ring-opening reaction was monitored by the following reverse phase HPLC method:
[0182] A) Reverse phase HPLC conditions: Agilent 1100 HPLC, 1 ml / min, 40°C column temperature, 230 nm UV detection, mobile phase: solvent x (0.1% TFA in water) and solvent y (Acn / MeOH (1:1 v / v)). Method: Gradient: solvent x 5% to 50% in 50 minutes, and then 50% to 100% in 5 minutes. Column: Supelco Ascentis ExpressC18 150x 4.6 2.7 μm, injection volume 5 μL. Samples were prepared by diluting 10 μL of reaction mixture / mother liquor with 1 mL of water / acetonitrile containing citric acid or 0.5 mg / mL in solvent y for solid samples. Retention time: chloropyridone (4.5 minutes), O-alkylated pyridine (12.7 minutes), N-alkylated pyridine (R2; 7.7 minutes), compound 2.1 (13.6 minutes), compound 2.3 (18.4 minutes) and compound of formula (1) (11.8 minutes).
[0183] B) Reverse phase chiral HPLC conditions: Agilent 1100 HPLC, 0.7 ml / min, 15°C column temperature, UV detection at 218 and 230 nm, mobile phase: solvent x (0.1% TFA in water) and solvent z (Acn). Method: Isocratic: solvent z 20% for 25 min; and column: Regis (S,S)-Whelk-01 250x 4.6mm 5μm, catalog number 780101, injection volume concentration is 0.1mg / mL in 1:1 Acn / water 20μL (rc1) sample. Retention time of 4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (rc2): R-enantiomer (R2, 8.98 minutes), and for S-enantiomer, 9.58 minutes.
[0184] Preparation of reactants, intermediates (compounds) and formula (1)
[0185] Potassium 4-chloro-2-oxo-2H-pyridinium-1-one
[0186]
[0187] The compound is prepared by reacting 4-chloropyridin-2(1H)-one in a solvent mixture of toluene / ethanol / water in the presence of KOH at a starting temperature of about 5° C. and ending at about 20° C. Alternatively, the pyridinium anion can be prepared in situ by reacting 4-chloropyridin-2(1H)-one with potassium tert-butoxide (KOtBu).
[0188] Process (rxn-1) for preparing (rc1): 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one:
[0189]
[0190] Intermediate (b): 3-(Methylsulfonyl)dihydrofuran-2(3H)-one
[0191] In a 4-necked round bottom flask (500 mL) equipped with overhead stirring, heating mantle and temperature controller under nitrogen was charged 3-bromotetrahydrofuran-2(3H)-one ((a), 100.0 g, 0.576 mol, 1.00 equiv), sodium methanesulfinate (90.0 g, 85% potency, 0.750 mol, 1.30 equiv), 336 (1.5 g, 3.7 mmol, 0.0064 equiv), magnesium sulfate (6.0 g) and isopropanol (250 mL). The resulting mixture was heated to 80°C. After 3 hours, 1 The product (b) of (rc1) is prepared by mixing with 1% paraformaldehyde (I) and 1% paraformaldehyde (I) in 4% paraformaldehyde (I).H-NMR shows that the reaction is completed.Ice bath cooling is used to cool the reaction mixture to room temperature.The solid produced is separated by filtering, washed with Virahol (100mL), and dried in a vacuum, to obtain the mixture of 176g intermediate (b) and inorganic salts.Alternately, can be by being dissolved in acetone, filter out NaBr, and acetone filtrate is carried out to solvent evaporation to cleanly isolate the product (b) of expectation.Subsequently, the dried solid from above is used for next step to prepare (rc1).
[0192] Intermediate (rc1): 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one
[0193] Intermediate (b) (94 g, 0.576 mol, 1.00 eq.) from the above solid mixture was extracted with acetone (2 x 100 mL) at 45 °C (complete extraction verified by gravimetric analysis (total weight loss 94 g) and HPLC (no product detected in the cake after the second extraction)). The acetone extract was then charged under nitrogen with: potassium carbonate (325 mesh, 100 g, 0.724 mol, 1.26 eq.), 336 (1.5 g, 3.7 mmol, 0.0064 eq), dimethyl sulfate (68 mL, 0.719 mmol, 1.25 eq) and magnesium sulfate (6.0 g). The reaction mixture was heated to 60 °C for 7 hours. 1H NMR analysis showed 3% of (b) remaining. Another 7g of dimethyl sulfate and 10g of potassium carbonate were charged into the reactor, and heating was maintained for another 4 hours. The reaction mixture was filtered to remove inorganic salts. The solid was washed with acetone (100mL). The filtrate was heated to 65°C, and acetone was distilled from the reaction tank until 200mL or about 1.5 volumes of liquid remained. At this point, isopropanol (200mL) was solvent exchanged with a constant reactor volume. The isopropanol solution was cooled to 35°C and seeded. Further cooling to 25°C induced crystallization. The crystals were filtered and washed with 100mL of isopropanol. 93g of (rc1) was isolated as an off-white crystalline solid (91%), mp 74°C, 1 H NMR (600 MHz, CHLOROFORM-d) δ ppm 4.49-4.56 (m, 1H), 4.35-4.44 (m, 1H), 3.16-3.22 (m, 1H), 3.08 (s, 3H), 2.31 (dt, J=14.63, 8.83 Hz, 1H), 1.74 (s, 3H).
[0194] Alternatively, (rc1) can be prepared without isolating intermediate (b) by telescoping the reactions (rxn-t) as shown below:
[0195]
[0196] A 30 L jacketed reactor equipped with overhead stirring, temperature controller and reflux condenser was charged with 3-bromotetrahydrofuran-2(3H)-one (a) (2.5 kg, 96% potency, 14.4 mol, 1.00 equiv), sodium methanesulfinate (2.0 kg, 85% potency, 16.7 mol, 1.16 equiv) and 1.5 g of 3-bromotetrahydrofuran-2(3H)-one (a) (2.5 kg, 96% potency, 14.4 mol, 1.00 equiv) under nitrogen. 336 (30 g, 74.2 mmol, 0.005 eq), magnesium sulfate (120 g, 0.07 eq) and acetone (7.5 L, 3 volumes). The resulting mixture was heated to reflux (56 ° C). After 9 hours, HPLC showed that the starting material was <1%. The reaction mixture was cooled to ambient temperature and allowed to stir overnight. The reaction mixture was filtered and the solid was washed with 200 mL of acetone. A 2 mL sample of the acetone filtrate was concentrated in vacuo to obtain a solid (b). 1 HNMR(600MHz,DMSO-d6)δ4.75(dd,1H),4.37(m,2H),2.64(m,2H).
[0197] The acetone filtrate from above (8.3 kg) was added to a 30 L jacketed reactor equipped with overhead stirring, a temperature controller, and a reflux condenser. To this solution was added anhydrous potassium carbonate (2.73 kg, 325 mesh, 1.37 eq), dimethyl sulfate (2.27 kg, 1.25 eq), and anhydrous magnesium sulfate (120 g, 0.07 eq). The mixture was slowly heated to reflux (56 ° C). After 15 hours at reflux temperature, additional potassium carbonate (200 g, 0.1 eq) and dimethyl sulfate (200 g, 0.11 eq) were added, and reflux was continued for another 4 hours. The mixture was cooled to ambient temperature, and the reaction mixture was filtered to remove inorganic salts. The solid was washed with acetone (2 L, 0.8 volume). The filtrate was heated to 65 ° C, and acetone was distilled from the reaction tank until 3 L of liquid remained. At this time, a solvent exchange was performed from acetone to isopropanol (4 L) at a constant reactor volume. After all the isopropanol was dripped into the reactor, the solution was cooled to 35°C and seeded. Further cooling to 25°C induced crystallization. The mixture was further cooled to 20°C and maintained at that temperature for 1 hour. The crystals were filtered and washed with 2L of isopropanol. The wet cake was dried in vacuo at 40°C overnight to give 2.0 kg of (3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one as an off-white crystalline solid (78%), mp 74°C, 1 H NMR (600MHz, Chloroform-d) δppm 4.49-4.56 (m, 1H), 4.35-4.44 (m, 1H), 3.16-3.22 (m, 1H), 3.08 (s, 3H), 2.31 (dt, J = 14.63, 8.83Hz, 1H), 1.74 (s, 3H).
[0198] A separate synthesis for the preparation of (rc1) from intermediate (a) using the above procedure but without the use of a dehydrating agent (ie, magnesium sulfate) during the sulfonylation and methylation reactions provided (rc1) in 64% yield.
[0199] A separate synthesis for the preparation of intermediate (b) from intermediate (a) without magnesium sulfate and replacing acetone with isopropanol provided intermediate (b) in 83% yield. A 2-necked round bottom flask equipped with a magnetic stir bar, heating mantle and temperature controller was charged with 3-bromotetrahydrofuran-2-one ((a), 4.0 g, 24.2 mmol, 1.00 equiv), sodium methanesulfinate (3.0 g, 28.3 mmol, 1.2 equiv), 336 (0.12 g, 0.50 mmol, 0.02 equiv), isopropanol (12 mL). The resulting mixture was heated to 80°C. After 3 hours, 1H-NMR (600MHz, DMSO-d6) indicates that the reaction is complete. Use an ice bath to cool the reaction mixture to ambient temperature. The resulting solid is separated by filtration, washed with isopropanol (5mL), and concentrated in vacuo to obtain a white solid. The solid is reslurried in acetone (20mL) and filtered to remove sodium bromide. The mother liquor is concentrated in vacuo to obtain a white solid, 3.3g (83%), Table 1.
[0200] Similar preparations of sulfonyl lactones (b) were carried out from intermediate (a) using different solvents as shown in Table 1 without the use of magnesium sulfate.
[0201] Table 1: Different solvents used for the preparation of intermediate (b).
[0202] Solvents Yield (%) Isopropyl alcohol 83 Ethanol (3 vol) 72 Methanol (3 vol) 67 Acetonitrile (3 vol) 68
[0203] Without using dehydrating agent magnesium sulfate, also changing alkali, methylating agent and / or solvent, carry out the small-scale preparation of methylsulfonyl lactone (rc1) by intermediate (b) as mentioned above. (rc1) yield of each reaction from these reactions is shown in Table 2.
[0204] Table 2: Different reactants and / or solvents used to prepare (rc1).
[0205]
[0206] General procedure for lactone ring opening: Synthetic intermediate 4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (rc2)
[0207]
[0208] Under nitrogen in a 125 mL Mettler Easy Reactor (stir speed 400RPM) or the 40mL scintillation vial with magnetic stirring apparatus, react.Potassium tert-butoxide (9.89g, 87.3mmol, 1.01 equivalents) is dissolved in anhydrous dimethyl sulfoxide (23mL), and add in anhydrous dimethyl sulfoxide (11mL) containing 4-chloro-2-hydroxypyridine (that is, 4-chloropyridine-2 (1H)-one (tautomer)) (11.2g, 86.5mmol, 1.00 equivalent), internal temperature is maintained between 18-27 ℃ simultaneously.After 15 minutes, add (rc1) (16.5g, 92.6mmol, 1.07 equivalents) and benzyltriethylammonium bromide (1.21g, 4.44mmol, 0.0514 equivalent) mixture by a part.Reaction mixture is heated to 85 ℃ and continues 2 hours, and sampled, to carry out HPLC analysis. HPLC chromatogram demonstrates 30.7% chloropyridone, 65.2% (rc2) and 4.1% O-alkylated product 5-((4-chloropyridin-2-yl) oxygen base)-2-methyl-2-(methyl sulfonyl) valeric acid.Then make reaction mixture aging 17 hours (total reaction time 19 hours) and resample at 85 ℃.HPLC indicates 5% chloropyridone, 88.1% (rc2) and 2.4% O-alkylated compound.When hot, reaction mixture is handled with isopropyl acetate (50mL), and transferred in the 400mL reactor.Mixture is handled with other isopropyl acetate (100mL), stirred 1 hour at 60 ℃ jacket temperature.Make chuck cool to 20 ℃ in 1 hour, and age 1 hour. The resulting solid was isolated by filtration, washed with isopropyl acetate (2 x 30 mL), and dried at 50 °C overnight to afford 25.75 g (86%) of (rc2) (potassium salt) as an off-white solid.
[0209] Synthesis of free carboxylic acid (rc2)
[0210] To 5.0 grams of above potassium salts dissolved in water (15mL), and with methanol (10mL) and Me-THF (4mL) processing.Then, fill 1.8mL concentrated HCl.The pH of slurry is about 1.The slurry was stirred at room temperature for 2 hours, and then cooled to 0-5 ℃, and stirred one hour at said temperature.The slurry is filtered and washed with water: methanol (8:2), and then dried in a vacuum under the situation of nitrogen loss, to obtain 4.04 grams (rc2) (90.8%). 11H NMR (600 MHz, DMSO-d6) δ ppm 1.55 (s, 3H) 2.14 (ddd, J = 13.39, 10.18, 4.86 Hz, 1H) 2.42 (ddd, J = 13.34, 10.22, 5.96 Hz, 1H) 3.14 (s, 3H) 3.92 (ddd, J = 12.84, 10.18, 5.96 Hz, 1H) 4.03 (ddd, J = 12.88, 10.22, 4.95 Hz, 1H) 6.37 (dd, J = 7.34, 2.38 Hz, 1H) 6.52 (d, J = 2.38 Hz, 1H) 7.76 (d, J = 7.15 Hz, 1H) 13.85 (br s, 1H). 13 13C NMR (151 MHz, DMSO-d6) δ ppm 14.70, 31.65, 36.91, 44.20, 69.36, 106.82, 117.74, 139.97, 145.66, 160.33 and 169.18.
[0211] Alternatively, (rc2) is prepared according to the following procedure. Under nitrogen, 400 mL reactor is loaded with PEG 400 (15.6 g, 38.6 mmol, 0.20 equivalent), 2-methyl-2-butanol (175 mL, 7 V) and 4-chloro-2-hydroxypyridine (25.0 g, 193 mmol, 1.0 equivalent). The jacket temperature is adjusted to 20 ° C, and potassium tert-butoxide (23.0 g, 201 mmol, 1.041 equivalent) is added while stirring with mechanical stirring (300-600 rpm). Note: the internal temperature rises from 19 ° C to 42 ° C. In order to control large-scale exothermicity, KOtBu is added in part. The reaction mixture is aged at 40-45 ° C for 30-45 minutes; then (a portion) is loaded with 3-methyl-3-methylsulfonyl-tetrahydrofuran-2-one (38.6 g, 212 mmol, 1.10 equivalent). Reactor jacket was heated to 100°C in 20 minutes, and maintained for 16-20 hours (internal temperature was 95-98°C). When 4-chloro-2-hydroxypyridine was less than 5% a / a (HPLC or NMR), it was considered that the reaction was complete. Then the reaction mixture was cooled to 50-60°C, diluted with water (63mL, 2.5V), and pH was adjusted to 1-2 using concentrated HCl (about 20mL). Then, the reaction mixture was cooled to 0°C in 2 hours, aged for 1 hour, and the solid produced was separated by filtration. The product was washed with deionized water (2x 40mL), and dried to constant weight at 70°C in a high vacuum to obtain 46.5g (78.3%) of 4-(4-chloro-2-oxopyridine-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid in a gray crystalline solid. HPLC purity 98.4% a / a at 230nm. 1HNMR(600MHz,DMSO-d6)δppm 1.55(s,3H)2.14(ddd,J=13.39,10.18,4.86Hz,1H)2.42(ddd,J=13.34,10.22,5.96Hz,1H)3.14(s,3H)3.92(ddd,J=12.84,10.18,5. 96Hz, 1H) 4.03 (ddd, J = 12.88, 10.22, 4.95Hz, 1H) 6.37 (dd, J = 7.34, 2.38Hz, 1H) 6.52 (d, J = 2.38Hz, 1H) 7.76 (d, J = 7.15Hz, 1H) 13.85 (br s,1H). 13C NMR (151 MHz, DMSO-d6) δ ppm 14.70, 31.65, 36.91, 44.20, 69.36, 106.82, 117.74, 139.97, 145.66, 160.33 and 169.18.
[0212] (rc2) Classic split into (R2)
[0213] To (rc2) (1.0 equivalent) in the slurry in methanol (5mL / g), slowly add (30-60 minutes) (S)-(+)-α-methylbenzylamine (1.05 equivalent) in methanol (1 volume), while maintaining temperature between 55 ℃ and 65 ℃.Reaction is heated at 65 ℃ for 30 minutes, then slowly cooled to 60 ℃.Mixture is seeded and cooled to 0 ℃ in the time period of 5 hours, and aged 2 hours.Slurry is filtered, and washed with IPA (2x 1 volume), and dried overnight at 55 ℃ under vacuum, to obtain desired diastereoisomer salt (18.95kg; 44% yield and 98.93% purity).
[0214] Synthesis of (R2) from (R1)
[0215] A sample of (R2) was prepared using the general procedure shown above for (rc2) to (R2) starting from 4-chloro-2-hydroxypyridine (1.14 g, 8.80 mmol) and (R1) (i.e., 3-methyl-3-methylsulfonyl-tetrahydrofuran-2-one) (1.65 g, 9.26 mmol). 1.63 g (R2) (60%) was isolated. HPLC purity 96.4% (achiral); chiral HPLC R f 8.98 minutes, purity 99.9%.
[0216] Chiral Chromatography for the Separation of (R1) from (R)-3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one and (S)-3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one
[0217]
[0218] A total of 5 g of the racemate (rc1) was passed through a 30 x 250 mm 5 μDaicel HPLC system with UV detection at 230 nm. Preparative Sepiatec SFC 250 instrument for AD-H column. The column was eluted with: mobile phase A (CO2) and mobile phase B (MeOH); isocratic 25% B; 90 / ml / min, 140 bar back pressure. The (R) enantiomer was the first eluting peak at 2.4 minutes, and the second eluting peak (S) eluted at 2.8 minutes. The eluent was evaporated using a rotary evaporator and the residue was lyophilized from a mixture of acetonitrile / water. The HPLC chiral purity of the first peak (2.15 g, 43%) was >99%, while the HPLC chiral purity of the second peak (2.32 g, 46%) was 96.0%. Peak assignment was performed by comparing the retention time of each peak with that of its corresponding reference standard. Reference standard:
[0219] ●(R)-3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one, optical rotation 0.198[α] 20 589 = -9.960° (2, 0.5, MeOH) and melting point 94°C
[0220] ●(S)-3-Methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one, optical rotation +0.184[α] 20 589 = +9.250° (2, 0.5, MeOH) and melting point 92°C
[0221] Synthesis of (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butyric acid (S)-1-phenylethane-1-ammonium
[0222]
[0223] 4-(4-chloro-2-oxopyridine-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (rc2) (49.95g, 162.3mmol, 1.0 equivalent) is loaded into 400mL reactor, followed by methanol (200mL, 4 volumes). The reaction mixture (slurry) is heated to 55-60°C (target 60°C internal temperature) in the time period of 0.5 hour to 1.5 hours. A solution of (S)-α-methylbenzylamine (20.76, 171.3mmol, 1.056 equivalent) in methanol (25mL, 0.5 volume) is prepared in a separate reactor. A solution of (S)-α-methylbenzylamine in methanol is transferred to the reactor containing the racemate in the time period of 30 minutes. After adding 80% of the solution, the slurry becomes a clear solution. The reactor and transfer line are rinsed with methanol (12mL, 0.25 volume), and added to the reaction mixture. The reaction mixture was then heated to reflux (65° C.) over a period of 0.5 to 1 hour, aged at 65° C. for 0.5 to 1 hour, and cooled to 60° C. over 30 minutes. The reaction mixture was seeded with (S)-1-phenylethan-1-ammonium (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoate (0.250 g 0.5% racemic input). Note: If the seed dissolved, cool to 55° C. over 30 minutes and re-seed the mixture with (S)-1-phenylethan-1-ammonium (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoate (0.250 g 0.5% racemic input). The reaction mixture was aged at 60°C for 1-3 hours to initiate crystallization and cooled to -5°C to 5°C (target 0°C) within 4-10 hours (target 5 hours). The reaction mixture was aged at -5°C for 1 hour and the resulting solid was isolated by filtration. The product was washed with IPA (2 x 25 mL, 0.5 volume each) and dried under vacuum at 55-65°C for not less than 10 hours to give 30.6 g of (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (S)-1-phenylethane-1-ammonium (44%) as a white crystalline solid.
[0224] Synthesis of (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (R2)
[0225]
[0226] A 30 L glass reactor was charged with (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (S)-1-phenylethane-1-ammonium (2.655 kg, 5.757 mol, 1.0 eq) and 25% IPA in water (15 L, 5.6 vol). The resulting mixture was heated to 35°C to 45°C (target 40°C) over 30 minutes and while maintaining the temperature, concentrated HCl (0.264 L / kg, 1.25 eq, about 11 N) was slowly charged until the pH was between 1.0 and 2.0. Note that in the current example, 662 mL of concentrated HCl was added to obtain a pH of 1.4. The mixture was aged at about 45°C for 0.5 hours, then cooled to 0°C over a period of 2 hours and aged at 0°C for 0.5 hours. The resulting solid was isolated by filtration, washed with water (2 x 2 L, 0.75 vol each), and dried under vacuum at 65° C. with nitrogen bleed to give 1.785 kg of (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (R2) (100%). Optical rotation = +0.425 [α] 23 589 = +42.500° (2, 0.5, MeOH)
[0227] Borylation: Synthesis of 2-(4-(1,3,2-dioxaborolan-2-yl)phenyl)-2H-1,2,3-triazole
[0228]
[0229] A solution of 2,2'-bis(1,3,2-dioxaborolane) in ethanol was prepared in a suitable container (12L flask, container 1) equipped with a mechanical stirrer and a temperature indicator by mixing tetrahydroxydiboron (0.398kg, 4.306mol, 1.50 equiv), ethylene glycol (0.481kg, 7.753mol, 2.699 equiv) and 200 proof ethanol (4L, 8 volumes). The slurry was stirred at about 20-25°C without heating until a clear solution was observed (NLT 3 hours). The solution can be stored for up to 24 hours at ambient temperature under a nitrogen purge. Ethanol (4.8L, 9.5 volumes), acetic acid (84.5g, 1.4mol, 0.489 equiv) were charged in a separate container (container 2), and the resulting solution was degassed using nitrogen for about 10 minutes. Then, 2-(4-chlorophenyl)-2H-1,2,3-triazole (0.516 kg, 2.872 mol, 1.000 equiv), pre-dried potassium acetate (0.691 kg, 6.97 mol, 2.43 equiv), XPhosG2 (4.43 g, 5.52 mmol, 0.002 equiv), and XPhos (5.37 g, 11.0 mmol, 0.004 equiv) were added. The reaction mixture was heated to about 50-60° C., aged for 15-30 minutes, and then cooled to reach an internal temperature of about 40-50° C. The solution in vessel 1 was degassed with nitrogen for about 10 minutes, and then transferred to the reaction mixture in vessel 2 using nitrogen pressure while maintaining an internal temperature of about 45-60° C. (Note: the reaction is exothermic). The transfer line was flushed with degassed ethanol (1 volume). The reaction mixture is then aged at an internal temperature of 50-60°C for about 1 hour and sampled to check the reaction conversion. The reaction is considered complete when the residual aryl chloride is less than 0.5% (a / a). If the residual aryl chloride is above 0.5% aa, additional tetrahydroxydiboron (1.5 equiv.) relative to the % of unreacted 2-(4-chlorophenyl)-2H-1,2,3-triazole can be added. Note: The limiting reagent for this step is 2-(4-chlorophenyl)-2H-1,2,3-triazole. Alternatively, the borylation step can be performed in a one-pot process.
[0230] Alternatively, for the Suzuki coupling reaction, 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2H-1,2,3-triazole can be prepared
[0231]
[0232] The complex [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) and dichloromethane (280mg, 0.34mmol) were added to a mixture of 2-(4-bromophenyl)-2H-1,2,3-triazole (255mg, 1.14mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis-1,3,2-dioxaborolane (350mg, 1.38mmol) and potassium acetate (340mg, 3.46mmol) in 1,4-dioxane (10mL). The reaction mixture was heated to 80°C and stirred overnight at this temperature. The reaction mixture was allowed to cool to room temperature and diluted with ethyl acetate (30mL) and brine (30mL). The mixture was filtered through diatomaceous earth (about 1 inch). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2x 30mL). The organic layers were combined, dried (MgSO4), filtered, and concentrated in vacuo. The crude material was purified by flash chromatography using an Analogix SF15-12 g column and a gradient of 0-10% ethyl acetate / n-heptane to give an orange solid (240.6 mg, 78%). 1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 8.59 Hz, 2H), 7.94 (d, J = 8.59 Hz, 2H), 7.83 (s, 2H), 1.36 (s, 12H). LCMS: m / z 272.4 [M+H]+.
[0233] Suzuki coupling: Synthesis of (R)-4-(4-(4-(2H-1,2,3-triazol-2-yl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (2.1)
[0234]
[0235] A separate reactor (Container 3) was charged with deionized water (6 L, 6.9 vol), sodium carbonate (0.745 g, 7.036 mol, 2.5 eq), (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (0.866 kg, 2.814 mol, 1.0 eq) and stirred at about 20-30°C until a solution was observed. The sodium carboxylate solution was degassed using nitrogen for about 10 minutes. The degassed solution was then added to the reaction mass in Container 2, which contained 2-(4-(1,3,2-dioxaborolan-2-yl)phenyl)-2H-1,2,3-triazole, while maintaining an internal temperature of about 50-60°C. After the addition was complete, the original container and transfer line were rinsed with degassed deionized water (1 vol). The reaction mixture was heated to about 70-80°C, aged for 3 hours, and sampled for HPLC analysis. The reaction was considered complete if the residual 2-(4-(1,3,2-dioxaborolan-2-yl)phenyl)-2H-1,2,3-triazole was less than 0.5% a / a. In the case where the residual 2-(4-(1,3,2-dioxaborolan-2-yl)phenyl)-2H-1,2,3-triazole was above 0.5% aa, additional (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-butanoic acid (0.025 equiv) could be added. The reaction mixture was cooled to about 50-60°C and 2-methyltetrahydrofuran (3.2 L, 3.7 vols) was charged while maintaining the internal temperature between 50-60°C. The mixture was further cooled to reach an internal temperature of about 40-50°C. Then, concentrated hydrochloric acid (961 mL, 1.11 volumes) was slowly loaded while maintaining an internal temperature of about 40-50°C. If no solid was observed, additional concentrated hydrochloric acid (0.1 volume) was loaded. The reaction mixture was aged for about 1 hour at an internal temperature of about 40-50°C, and then the pH was adjusted to 1 using concentrated HCl (961 mL, 1.1 volumes) while maintaining an internal temperature of about 40-50°C. Note: pH must be NMT 1. Finally, the batch was cooled to about 0-10°C and aged for no less than 1 hour. The product was separated by filtration, and the wet cake was washed with a mixture (1:1 v / v) of ethanol / deionized water (4 L), followed by washing with deionized water (1.65 L). The product was transferred to a desiccator and dried under vacuum at a jacket temperature not exceeding 65°C until the LOD was below 0.5 w / w% to give 1.153 g of (R)-4-(4-(4-(2H-1,2,3-triazol-2-yl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (2.1) as a light beige solid (98%). 1H-NMR(600MHz,DMSO-d6)δppm 1.55(s,3H)2.14(m,1H)2.42(m,1H)3.14(s,3H)3.92(m,1H)4.03(m,1H)6.37(dd,1H)6.52(d,1H)7.76(d,1H)13.85(br s,1H).
[0236] Acid chloride formation: Synthesis of (R)-4-(4-(4-(2H-1,2,3-triazol-2-yl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoyl chloride (2.2)
[0237]
[0238] A dry 30 L jacketed glass reactor connected to a basic scrubber (the reaction will evolve gaseous HCl, CO2, and CO) was charged with dichloromethane (10 L, 10 vol) followed by oxalyl chloride (0.908 kg, 7.150 mol, 2.980 eq) and N,N-dimethylformamide (10 mL, 129 mmol, 0.0538 eq) at 20°C under nitrogen. Then, (R)-4-(4-(4-(2H-1,2,3-triazol-2-yl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid 2.1 (1.000 kg, 2.401 mol, 1.0 eq) was slowly charged (NLT 30 min) while maintaining an internal jacket temperature of about 20-35°C. Note: gas evolution is expected. The reaction mixture is aged at 20-40°C for 90-120 minutes (target 30°C), and sampled for HPLC analysis. When carboxylic acid <5% (target <3%), the reaction is considered complete. Note: The conversion is determined by quenching 2 drops of raw material with 2mL of anhydrous methanol. Excess oxalyl chloride / DCM is distilled out at atmospheric pressure to become a viscous slurry (minimum volume 1-2L), and then heptane (5L, 5 volumes) is filled). Distillation is continued until the internal temperature of the jacket reaches 96-98°C (viscous slurry). Note: A mixture of acid chlorides in heptane can be stored overnight at room temperature under nitrogen. The final volume in the tank is about 1-2L. Alternatively, excess oxalyl chloride can be removed by a series of decantation separation / DCM dilutions or by adding a controlled amount of water at low temperatures (-5°C to 5°C).
[0239] Amide bond formation - Synthesis of (2R)-4-(4-(4-(2H-1,2,3-triazol-2-yl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-((tetrahydro-2H-pyran-2-yl)oxy)butyramide (2.3)
[0240]
[0241] The above reaction was cooled to 20-30°C, diluted with dichloromethane (7.3 L, 7.3 vols), and then cooled to -5°C to 5°C. 4-Methylmorpholine (0.777 kg, 7.682 mol, 3.199 eq) was slowly charged to the cold reaction mixture while maintaining the temperature below 10°C. Note: It is extremely important to control moisture; 4-methylmorphine should be reagent grade or better. In a separate reactor, a solution of O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (THP-ONH2; 0.337 g, 2.885 mol, 1.202 eq) in dichloromethane (3.4 L, 3.4 vols) was prepared. The water content of the solution must be less than 500ppm, if it is higher than 500ppm, it must be azeotropically dried as follows: distill 40% of the batch volume, and then add anhydrous DCM, sample for Karl Fisher titration, repeat until the water content is less than 500ppm. Slowly transfer the THP-ONH2 solution to the acid chloride over 40 minutes while keeping the temperature below 10°C (target -5°C to 5°C). Then, flush the transfer line with dichloromethane (1L, 1 volume). Use pH test paper to check the apparent pH of the reaction mixture. If it is not between 7-10, additional 4-methyl-morpholine must be loaded until the apparent pH is adjusted to the desired range. Then, age the reaction mixture at -5°C to 5°C for 1-2 hours; heat to 20-30°C within 1-3 hours, and keep at 20-30°C for not less than 30 minutes. Sample the reaction mixture to check the conversion using HPLC. Residual acid chloride is measured by converting acid chloride into methyl ester. When acid chloride is less than 0.5%, it is considered that the reaction is complete. Then, a small amount of water (330mL) is filled, and the reaction mixture is aged for no less than 30 minutes. The product is separated as follows: the reaction mixture is concentrated by distillation at atmospheric pressure (reactor jacket temperature 60°C), to remove 7L DCM, and then diluted with methanol (8L, 8 volumes). Distillation is continued at atmospheric pressure, and the jacket temperature is 60-80°C, to remove 7-8 volumes of DCM / MeOH. Finally, methanol (5L, 5 volumes) is filled, and distillation is continued at atmospheric pressure at a jacket temperature of 80-90°C, until the internal temperature reaches 65-70°C (target 67°C). About 5L distillate is collected. Then the reaction mixture is cooled to -5°C to 5°C (target 0°C) in no less than 2 hours, aged 1 hour at the target temperature, and the solid produced is separated by filtration. The product was washed with methanol (3 x 1 L), combined, dried for 30 minutes, and dried under vacuum at 50-60 °C to give 1.223 kg of product (98.8% yield) with HPLC purity of 95.9%. 1H-NMR(600MHz,DMSO-d6)δppm 1.53(m,3H)1.59(d,3H)1.69(m,3H)2.14-2.27(m,1H)2.37-2.48(m,1H)3.11(d,3 H)3.44-3.63(m,1H)3.65-3.93(m,1H)3.96-4.11(m,1H)4.11-4.32(m,1H)4.98(br s,1H)6.61 -6.77(m,1H)6.79(m,1H)7.79(dd,1H)7.96(m,2H)8.04-8.16(m,2H)8.18(s,2H)11.63(br s,1H).
[0242] Synthesis formula (1): (R)-4-(4-(4-(2H-1,2,3-triazol-2-yl)phenyl)-2-oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butyramide
[0243]
[0244] A 30 L glass reactor was charged with an aqueous solution (6.3 L, 6.30 mol, 1.54 equiv) containing (2R)-4-(4-(4-(2H-1,2,3-triazol-2-yl)phenyl)-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-((tetrahydro-2H-pyran-2-yl)oxy)butanamide 2.3 (2104 g, 4.08 mol, 1.00 equiv), 2-propanol (21 L, 10 volumes) and HCl (1 mol / L). Alternatively, a reaction solvent containing 0.025-1 equivalent of sulfuric acid or a reaction solvent containing about 1 equivalent of maleic acid may also be used. The resulting mixture was heated to 60-70° C. while stirring at a rate of about 210 rpm and aged to 62-63° C. for about 40-60 minutes. Then, the reaction is sampled to confirm that the reaction is complete (i.e., <0.5%). If not completed, the reaction is continued for up to about 4 hours. After the reaction is complete, the reaction mixture is cooled to 20 ° (± 5 ° C) within 2-4 hours and aged for 1-2 hours at 20 ° C. The final product (formula (1)) is separated by filtration, washed with 2-propanol (4 L, 2 volumes), water (2 x 1.5 L), and dried at 55-65 ° C using room vacuum to obtain 1.665 kg (95%). 1H-NMR(600MHz,DMSO-d6)δppm 1.59(s,3H)2.18-2.21(m,1H)2.40-2.48(m,1H)3.11(s,3H)3.76-3.79(m,1H)4.12-4.16(m,1H)6.71(d d,1H)6.78(d,1H)7.79(d,1H)7.85-8.04(m,2H)8.04-8.15(m,2H)8.17(s,2H)9.24(s,1H)11.15(s,1H).
[0245] Alternatively, the final THP removal can be accomplished in the presence of a strong acid (e.g., HCl or HBr) in a solvent such as ethanol, isopropanol, acetone, acetic acid / tetrahydrofuran, or the like; or the compound of formula (1) can be prepared according to the procedures described in PCT Publication WO2019 / 178305 using iodopyridone or replacing it with chloropyridone; or according to the procedures described in U.S. Pat. No. 8,664,401.
[0246] Crystalline form
[0247] Multiple polymorphic forms (Forms 1, 2, and 3) of (R)-4-(4-(4-(2H-1,2,3-triazol-2-yl)phenyl)-2-oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)-butyramide were prepared as API slurries in a variety of protic and aprotic solvents. The use of aprotic solvents such as ethyl acetate, butyl acetate, or propyl acetate, in addition to acetonitrile, methyl ethyl ketone, and tetrahydrofuran, produced Form 1. The use of protic solvents such as butanol, propanol, and ethanol, in addition to water, favored the formation of Form 2. Unstable Form 3 was also noted. The presence of water in the alcohol increased the rate at which Form 2 separated from solution. Using pure water as the solvent produced primarily Form 1 in early experiments, but in expanded experiments, the solid isolated from pure water and analyzed quickly by XRD was found to be primarily Form 2. The three forms are structurally related and are solvated and / or hydrated. This tendency of the API to form solvates suggests that other crystalline solvates not described herein may be formed when the API is dissolved in solution and then crystallized by means such as antisolvent addition, cooling, or solvent evaporation.
[0248] The relative stabilities of the three isolated solid forms as suspensions appear to differ from the stability of the isolated solids. As an isolated solid, Form 1 is likely the most stable form. As a suspension, the relative stabilities of these solvates depend on the solvent or solvent / water mixture present. In solution, under certain conditions, Form 2 may be more stable than Form 1, but as an isolated solid, Form 2 is metastable relative to Form 1. Form 3 appears to be the kinetic form, being metastable and converting to Form 2. No XRD pattern of Form 3 plus Form 1 was observed, suggesting that Form 3 converts to Form 2, and Form 2 converts to Form 1.
[0249] Powder X-ray diffraction (XRD) pattern ( Figure 1 The relative peak positions, intensities and d-spacings of the three phase forms (Forms 1, 2, 3) and Forms 1 and 2 (Tables 3a and 3b) are very similar, which strongly suggests that the three phase forms share a substantially similar set of structural motifs. It is likely that the three solvated solids are nearly isostructural and differ slightly in a manner related to the way in which the solvent or water fills into the solvation sites in the structure. The complexity of the XRD patterns increases, with Form 1 being the most complex (most peaks) and Form 3 having the fewest peaks. This pattern complexity (F1>F2>F3) parallels the apparent stability of the dried, isolated samples. Of the 384 solvent mixtures, a total of 90 samples were mixtures rather than pure phase forms.
[0250] As will be appreciated by a skilled crystallographer, the relative intensities, positions and spacings of the various peaks reported in Tables (3a and b) and Figure (1) herein may vary due to many factors, such as the effects of orientation of the crystal in the X-ray beam or the purity of the material being analyzed or the degree of crystallization of the sample. The XRD peak positions may also shift due to changes in sample height, but the peak positions will remain essentially as defined in the table. A skilled crystallographer will also appreciate that measurements made using different wavelengths will produce different shifts according to the Bragg equation -nA, = 2ci sinθ. Such additional XRD patterns produced by using alternative wavelengths are considered to be alternative representations of the XRD patterns of the crystalline materials of the present invention, and are therefore within the scope of the present invention.
[0251] X-ray diffraction patterns were obtained on a Scintag X1 powder diffractometer equipped with a Peltier cooled solid state detector. Data were collected between 4° 2θ and 40° 2θ using a 0.03° step size, and for sample characterization, data collection time was 45 to 60 minutes. Data collection for solids isolated from most small-scale preliminary experiments was performed between 7° 2θ and 37° 2θ in 15 minutes at a 0.04° step size. Copper Kα radiation was used. The tube voltage and amperage were set to 45 kV and 40 mA, respectively. A quartz reference standard was used for instrument calibration.
[0252] Thermodynamic data do not clearly distinguish between forms that can be easily identified based on XRD patterns. Thermodynamic data indicate that all three solid forms are solvated, but the solvent content is variable. All samples (regardless of the form) show the same DSC melting point endothermic maximum peak (≈195°C) within 1°C. Thermodynamic analysis (differential scanning calorimetry (DSC)) of these samples was performed on a TA Instruments DSC 2920. The samples were placed in an aluminum DSC pan and the weight was accurately recorded. The lid and pan were assembled together, but not crimped, so that volatile components could escape. The samples were heated to 300°C at 10°C per minute.
[0253] Table 3a: Powder X-ray Diffraction Peak Data of Form 1
[0254]
[0255]
[0256] Table 3b: Powder X-ray Diffraction Peak Data of Form 2
[0257]
Claims
1. A compound of formula (rc1) which is 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one and stereoisomers thereof.
2. The compound according to claim 1, which is a compound of formula (R1) It is (R)-3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one.
3. A method for preparing a compound of formula (rc1) according to claim 1 and a stereoisomer thereof according to the following rxn-1 procedure: The method comprises: a) reacting 3-bromotetrahydrofuran-2(3H)-one (a) with sodium methanesulfinate in the presence of solvent A, a phase transfer catalyst and optionally a dehydrating agent at a temperature of about 40-100° C. for about 1-24 hours to prepare an intermediate 3-(methylsulfonyl)-dihydrofuran-2(3H)-one (b); b) allowing the mixture to cool at ambient temperature overnight, filtering the solid, and washing the solid with solvent A; c) reacting the solid with a base in the presence of a phase transfer catalyst, a methylating agent, a solvent B and optionally a dehydrating agent at a temperature of about 40-100° C. for a period of about 4-48 hours; d) charging the reactor with additional methylating agent and base while heating for an additional 4 hours; e) filtering the solid while retaining the solvent filtrate; f) washing the solid with solvent B while again retaining the solvent filtrate, and then heating the combined filtrates to about 65° C. while distilling off all but about 1.5 volumes of the filtrate; g) exchanging the solvent with solvent A, cooling and seeding; and h) further cooling to induce crystallization, filtering the crystals, and washing the crystals with solvent A to obtain the final product, i.e. 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (rc1).
4. The method of claim 3, further comprising a dehydrating agent selected from the group consisting of sodium sulfate, calcium chloride and magnesium sulfate.
5. The method according to claim 3 or 4, wherein solvent A is methanol, ethanol or isopropanol, solvent B is acetone or n-butanol, the base is selected from the group consisting of sodium carbonate, potassium carbonate, cesium carbonate and tripotassium phosphate, the phase transfer catalyst is selected from methyl trioctyl ammonium chloride, PEG 400 or PEG 300, and the methylating agent is selected from the group consisting of methyl iodide, methyl bromide, methyl chloride, methyl p-toluenesulfonate, dimethyl sulfate, dimethyl carbonate and diazomethane.
6. The method of claim 5, wherein solvent A is isopropanol, solvent B is acetone, the phase transfer catalyst is methyltrioctylammonium chloride or PEG 400, the methylating agent is dimethyl sulfate, and the base is sodium carbonate or potassium carbonate.
7. The method according to claim 6, comprising: a) reacting 3-bromotetrahydrofuran-2(3H)-one with sodium methanesulfinate in the presence of isopropanol, methyltrioctylammonium chloride and magnesium sulfate at a temperature of about 80° C. for about 3 hours to prepare an intermediate 3-(methylsulfonyl)dihydrofuran-2(3H)-one; b) allowing the mixture to cool overnight at ambient temperature and isolating the solid by dissolving in isopropanol, filtering the solid, and washing the solid with isopropanol; c) reacting the solid with potassium carbonate in the presence of methyltrioctylammonium chloride, dimethyl sulfate and magnesium sulfate in acetone at a temperature of about 60° C. for about 7 hours; d) charging the reactor with additional dimethyl sulfate and potassium carbonate while heating for an additional 4 hours; e) filtering the solid while retaining the acetone filtrate; f) washing the solid with acetone while again retaining the acetone filtrate and then heating the combined filtrates to about 65° C. while distilling off all but about 1.5 volumes of the filtrate; g) exchanging the acetone with isopropanol and cooling the mixture to about 35° C. and seeding; and h) further cooling to about 25° C. to induce crystallization, filtering the crystals, and washing the crystals with isopropanol to obtain 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (rc1).
8. A method for preparing a compound of formula (rc1) according to claim 1 and a stereoisomer thereof according to the following RXN-T procedure: The method comprises: a) reacting 3-bromodihydrofuran-2(3H)-one (a) with sodium methanesulfinate in the presence of a phase transfer catalyst, solvent B and optionally a dehydrating agent in a jacketed reactor at 50-80° C. for about 7-11 hours; b) allowing the mixture to cool to room temperature while stirring overnight for about 12 hours; filtering the reaction mixture, retaining the filtrate, and washing the solid with solvent B while retaining the filtrate; c) reacting the combined filtrates with a methylating agent, a base and optionally a dehydrating agent while slowly heating the reactants to about 50-80° C. for about 15-20 hours; d) adding more base and methylating agent to the mixture and heating for an additional about 3-6 hours; e) cooling the mixture to ambient temperature and filtering to remove solids while retaining the filtrate; f) washing the solid with solvent B while again retaining the filtrate and heating the combined filtrates to about 60-70° C. and then distilling off all but about 1.5 volumes of the solvent; and g) exchanging solvent B with solvent A while cooling to about 30-40° C. and seeding; then further cooling to about 20-25° C. to obtain 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (rc1).
9. The method of claim 8, further comprising a dehydrating agent selected from the group consisting of sodium sulfate, calcium chloride and magnesium sulfate.
10. The method according to claim 8 or 9, wherein solvent B is acetone, the phase transfer catalyst is methyl trioctyl ammonium chloride or PEG 400, the methylating agent is selected from the group consisting of: methyl iodide, methyl bromide, methyl chloride, methyl p-toluenesulfonate and dimethyl sulfate, and the base is selected from the group consisting of: sodium carbonate, potassium carbonate, cesium carbonate and tripotassium phosphate.
11. The method according to claim 7, comprising: a) reacting 3-bromodihydrofuran-2(3H)-one with sodium methanesulfinate in the presence of methyltrioctylammonium chloride, magnesium sulfate and acetone in a jacketed reactor at about 56° C. to reflux for about 9 hours; b) allowing the mixture to cool to room temperature while stirring overnight for about 12 hours; filtering the reaction mixture while retaining the filtrate and washing the solid with acetone, again retaining the filtrate; c) reacting the combined filtrates with dimethyl sulfate, anhydrous potassium carbonate and anhydrous magnesium sulfate while slowly heating the reactants to reflux at about 56° C. for about 15 hours; d) adding more potassium carbonate and dimethyl sulfate to the mixture and heating for about an additional 4 hours; e) allowing the mixture to cool to ambient temperature and filtering to remove solids while retaining the filtrate; f) washing the solid with acetone while again retaining the filtrate and heating the combined filtrates to about 65° C. and then distilling off all but about 1.5 volumes of acetone; and g) exchanging the acetone with isopropanol while cooling to about 35°C and seeding; and then further cooling to about 20°C to obtain 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one.
12. A method for preparing 4-(4-chloro-2-oxopyridine-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (rc2) from 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (rc1), the method comprising: a) dissolving potassium tert-butoxide in anhydrous DMSO and then adding 4-chloropyridin-2(1H)-one while maintaining the temperature between about 18-27°C; b) adding to a mixture of 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (rc1) and benzyltriethylammonium bromide and heating to about 85°C for 2 hours; c) aging the reaction at about 85° C. for about 17-20 hours; d) adding isopropyl acetate and stirring at about 60° C. for about 1 hour; e) cooling to about 20° C. over one hour and aging for one hour; filtering the solid, washing with isopropyl acetate, and drying at about 50° C. overnight to produce the potassium salt of 4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid; f) dissolving the dried solid in water, treating with methanol and methyltetrahydrofuran, and charging with concentrated HCl; g) stirring the slurry at room temperature for about 2 hours and cooling to about 0-5° C. while stirring for another hour; as well as h) The slurry was filtered and washed with water:MeOH (8:2) and then dried in vacuo under nitrogen to give 4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid.
13. A method for preparing 4-(4-chloro-2-oxopyridine-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (rc2) from 3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (rc1), the method comprising: a) charging a reactor with PEG 400, 2-methyl-2-butanol and 4-chloro-2-hydroxypyridine under nitrogen; b) adjusting the reactor temperature to about 18-25° C. and adding potassium tert-butoxide while stirring; c) aging the reaction mixture at about 40-50° C. for about 30-60 minutes; d) adding 3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one (rc1) to the reactor and heating to about 100° C. in about 15-30 minutes; e) maintaining the temperature at about 95-100° C. for about 12-24 hours; f) cooling the reaction to about 50-60° C., diluting with water, and adjusting the pH to about 1-2 with HCl; g) cooling the reactants to about 0-5° C. over about 1-3 hours, aging for about 1-2 hours, and filtering the resulting solids; and h) Wash the solid with water and dry to give 4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (rc2).
14. A method for preparing (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-butyric acid (R2) from (R)-3-methyl-3-(methylsulfonyl)-dihydrofuran-2(3H)-one (R1), the method comprising: a) dissolving potassium tert-butoxide in anhydrous DMSO and then adding 4-chloropyridin-2(1H)-one while maintaining the temperature between about 18-27°C; b) adding to a mixture of (R)-3-methyl-3-(methylsulfonyl)dihydrofuran-2(3H)-one and benzyltriethylammonium bromide and heating to about 85° C. for 2 hours; c) aging the reaction at about 85° C. for about 17-20 hours; d) adding isopropyl acetate and stirring at about 60° C. for about 1 hour; e) cooling to about 20° C. over one hour and aging for one hour; filtering the solid, washing with isopropyl acetate, and drying at about 50° C. overnight to produce the potassium salt of (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-butyric acid; f) dissolving the dried solid in water, treating with methanol and methyltetrahydrofuran, and charging with concentrated HCl; g) stirring the slurry at room temperature for about 2 hours and cooling to about 0-5° C. while stirring for another hour; as well as h) The slurry was filtered and washed with water:MeOH (8:2) and then dried in vacuo under nitrogen to give (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-butanoic acid.
15. A compound which is 4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid or (R)-4-(4-chloro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid.
